Skip to content
lifestyle.bossesmag.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
AtaiBeckley Inc.
AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations
June 1, 2026
AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026
May 31, 2026
AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update
May 29, 2026
AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst
May 22, 2026
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day
May 17, 2026
AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder
April 25, 2026
AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs
April 8, 2026